Tumour-associated macrophages drive stromal cell-dependent collagen crosslinking and stiffening to promote breast cancer aggression.

Journal Article (Journal Article)

Stromal stiffening accompanies malignancy, compromises treatment and promotes tumour aggression. Clarifying the molecular nature and the factors that regulate stromal stiffening in tumours should identify biomarkers to stratify patients for therapy and interventions to improve outcome. We profiled lysyl hydroxylase-mediated and lysyl oxidase-mediated collagen crosslinks and quantified the greatest abundance of total and complex collagen crosslinks in aggressive human breast cancer subtypes with the stiffest stroma. These tissues harbour the highest number of tumour-associated macrophages, whose therapeutic ablation in experimental models reduced metastasis, and decreased collagen crosslinks and stromal stiffening. Epithelial-targeted expression of the crosslinking enzyme, lysyl oxidase, had no impact on collagen crosslinking in PyMT mammary tumours, whereas stromal cell targeting did. Stromal cells in microdissected human tumours expressed the highest level of collagen crosslinking enzymes. Immunohistochemical analysis of biopsies from a cohort of patients with breast cancer revealed that stromal expression of lysyl hydroxylase 2, an enzyme that induces hydroxylysine aldehyde-derived collagen crosslinks and stromal stiffening, correlated significantly with disease specific mortality. The findings link tissue inflammation, stromal cell-mediated collagen crosslinking and stiffening to tumour aggression and identify lysyl hydroxylase 2 as a stromal biomarker.

Full Text

Duke Authors

Cited Authors

  • Maller, O; Drain, AP; Barrett, AS; Borgquist, S; Ruffell, B; Zakharevich, I; Pham, TT; Gruosso, T; Kuasne, H; Lakins, JN; Acerbi, I; Barnes, JM; Nemkov, T; Chauhan, A; Gruenberg, J; Nasir, A; Bjarnadottir, O; Werb, Z; Kabos, P; Chen, Y-Y; Hwang, ES; Park, M; Coussens, LM; Nelson, AC; Hansen, KC; Weaver, VM

Published Date

  • April 2021

Published In

Volume / Issue

  • 20 / 4

Start / End Page

  • 548 - 559

PubMed ID

  • 33257795

Pubmed Central ID

  • PMC8005404

Electronic International Standard Serial Number (EISSN)

  • 1476-4660

Digital Object Identifier (DOI)

  • 10.1038/s41563-020-00849-5


  • eng

Conference Location

  • England